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Abstract
Background: Studies have shown a slight excess risk in Guillain-Barré syndrome (GBS) incidence associated with
A(H1N1)pdm09 vaccination campaign and seasonal trivalent influenza vaccine immunisations in 2009–2010. We
aimed to assess the incidence of GBS as a potential adverse effect of A(H1N1)pdm09 vaccination.
Methods: A neurologist-led network, active at the neurology departments of ten general hospitals serving an adult
population of 4.68 million, conducted GBS surveillance in Spain in 2009–2011. The network, established in 1996, carried
out a retrospective and a prospective study to estimate monthly alarm thresholds in GBS incidence and tested them in
1998–1999 in a pilot study. Such incidence thresholds additionally to observation of GBS cases with immunisation
antecedent in the 42 days prior to clinical onset were taken as alarm signals for 2009–2011, since November 2009
onwards. For purpose of surveillance, in 2009 we updated both the available centres and the populations served by
the network. We also did a retrospective countrywide review of hospital-discharged patients having ICD-9-CM code
357.0 (acute infective polyneuritis) as their principal diagnosis from January 2009 to December 2011.
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Results: Among 141 confirmed of 148 notified cases of GBS or Miller-Fisher syndrome, Brighton 1–2 criteria in 96 %,
not a single patient was identified with clinical onset during the 42-day time interval following A(H1N1)pdm09
vaccination. In contrast, seven cases were seen during a similar period after seasonal campaigns. Monthly incidence
figures did not, however, exceed the upper 95 % CI limit of expected incidence. A retrospective countrywide review of
the registry of hospital-discharged patients having ICD-9-CM code 357.0 (acute infective polyneuritis) as their principal
diagnosis did not suggest higher admission rates in critical months across the period December 2009-February 2010.
Conclusions: Despite limited power and underlying reporting bias in 2010–2011, an increase in GBS incidence over
background GBS, associated with A(H1N1)pdm09 monovalent or trivalent influenza immunisations, appears unlikely.
Keywords: Guillain-Barré syndrome, Influenza A virus H1N1 subtype, Influenza vaccines, Public health surveillance,
Safety, ICD-9-CM
Background
Guillain-Barré syndrome (GBS) is an acute, acquired
immune-mediated polyradiculoneuropathy with mainly
motor symptoms, preceded in two thirds of cases by an
influenza-like or respiratory tract infection (ILI-RTI) or a
gastrointestinal tract infection (GTI). GBS presents with an
annual incidence of 1-2/100,000 in Western countries.
Although immunotherapy with intravenous gammaglobulin
(IVGG) considerably reduces mortality, GBS may cause se-
vere disability [1, 2].
An association between influenza vaccines and GBS was
previously described in 1976 and again in 1992–1994 [3–5].
Worldwide research, mainly using self-controlled case
series design [6] and self-controlled risk-interval de-
sign [7, 8], has addressed potential increases in GBS
incidence after vaccination campaigns against the 2009
pandemic influenza A(H1N1). Three meta-analyses, one
including US data obtained from six adverse event monitor-
ing systems [9], a pooled analysis across databases from 15
countries all over the world [10], and a meta-analysis of 16
published reports [11] showed a 2–3 fold excess risk in
GBS incidence associated with A(H1N1)pdm09 vaccines,
both adjuvanted and non-adjuvanted, when compared to
no vaccination. However, other cohort studies failed to sup-
port this association [12–14] or yielded undetermined find-
ings [15]. Although only a US study assessed the potential
increase over background GBS incidence following seasonal
or A(H1N1)pdm09 influenza vaccines, with negative re-
sults[16], it remains to be seen if occurrence of GBS attrib-
uted to A(H1N1)pdm09 vaccination exceeded previous
seasonal and monthly GBS estimates.
This study sought to assess occurrence of GBS as a
potential adverse effect of A(H1N1)pdm09 or seasonal
vaccinations by means of a special surveillance system
established to monitor GBS incidence during the vaccin-
ation programmes.
Methods
This study consisted of two parts, namely: a prospective
GBS surveillance system related to influenza vaccination,
and a retrospective assessment of GBS incidence in
Spain. In both parts, we attempted to detect incidence
rates that were higher than previously reported.
A(H1N1)pdm09 vaccine campaigns
In Spain, influenza vaccination is offered free of charge
each year to people in high-risk groups, those over
6 months old with chronic conditions, elderly people over
the age of 60 or 65 years depending on the region, health-
care workers, workers in essential public services, and
caregivers. The A(H1N1)pdm09 vaccine was not recom-
mended for elderly people without chronic disease.
2009 seasonal trivalent influenza vaccine
The vaccine included A/Brisbane/59/2007(H1N1), A/Bris-
bane/10/2007(H3N2) and B/Brisbane/60/2008 strains. In
the 2009 campaign, 10.2 million doses were administered
country-wide between weeks 40 to 48.
2009–2010 pandemic vaccine
The vaccine included the A/California/07/2009 (H1N1)
virus strain. The vaccine brands were Focetria® (Novar-
tis), adjuvanted with MF59, recommended to children
and the elderly, Pandemrix® (Glaxo SmithKline), adju-
vanted with ASO3, recommended for adults, and
Panenza® (Sanofi Pasteur), unadjuvanted, recommended
for pregnancy. Actual exposure involved administration
of 970,468 doses in the second half of November 2009,
641,829 in December 2009, 114,220 in January 2010,
coming to an end in late February 2010, making a total
of 1.7 million doses, less than 5 % of which were admin-
istered to persons under 18 years of age. In all, 12 % of
health care workers, 9 % of workers in essential public
services, 15 % of people from 18 to 60 years old with
chronic conditions, and 28 % of people 60 years old and
over received the vaccine (Division of Vaccination Pro-
grammes, Spain’s Ministry of Health, Social Services,
and Equality, unpublished report).
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2010 and 2011 campaigns
The vaccines included the A/California/07/2009 (H1N1),
A/Perth/16/2009 (H3N2) and B/Brisbane/60/2008 strains
[17, 18], a total of 8.1 million doses in each campaign.
In terms of vaccine effectiveness, estimates in Spain sug-
gest that the 2009-TIV had no protective effect,
A(H1N1)pdm09 vaccine had a good effect (66–78 %) and
2010-2011TIVs had a lower effect (50–55 %) [17–19].
Neurologist network
An 11-hospital neurologist network, conceived as a special
surveillance system [20], was established in 1996 to set
alarm thresholds in GBS monthly incidence, so that inci-
dence monitoring could be undertaken in situations where
risk was perceived. The National Centre for Epidemiology
at the Carlos III Institute of Health in Madrid co-
ordinated the network, which then covered an adult popu-
lation of 3.9 million. People under 20 years were not
covered. The network incorporated epidemiological fea-
tures of GBS in adults from 1985 to 1997 to estimate
upper limits in monthly incidences, and then conducted a
2-year pilot prospective study to update upper thresholds
in 1998–1999. As a result, the network estimated curves
with expected monthly incidences for all and certain age
groups [21, 22].
Surveillance design
At the request of the Spanish Agency of Medicines and
Medical Devices (Agencia Española de Medicamentos y
Productos Sanitarios/AEMPS), the National Centre for
Epidemiology, acting as a Central Unit, contacted net-
work members in August 2009 and re-established the
network to detect a potential GBS outbreak related to
A(H1N1)pdm09 vaccination. The eleven hospitals con-
stituting the original network remained functionally ap-
propriate for surveillance with minor changes in referral,
staff and catchment population but one hospital which
had difficulties in notifying cases was excluded. In Spain,
a national health service covers the majority of popula-
tion. To estimate incidence rates, each participant
hospital updated the number of people it covered. Of a
total of 36.9 million Spanish residents aged ≥20 years,
the population under surveillance numbered 4.68 mil-
lion, approximately 1/8 of the country population of that
age. Prospective notification to the Central Unit of all
patients suspected of presenting with GBS started in
September 2009, approximately one month before onset
of the A(H1N1) monovalent vaccine campaign, and
ended on 31 December 2011. Retrospective reporting
dated back to 1 January 2009. The Central Unit was
tasked with identifying potential outbreaks on the basis
of the information supplied by local neurologists, and,
when applicable, notifying these to the AEMPS.
Study subjects
A GBS case was defined by reference to the National Insti-
tutes of Neurological Disorders and Stroke (NINDS) cri-
teria [23]. Two months after notification of a suspected
case of GBS, local neurologists confirmed or excluded the
diagnosis on the basis of clinical, neurophysiological or
cerebrospinal fluid parameters. Miller-Fisher syndrome
(MFS) was not compulsorily reported. Each GBS or MFS
case was re-classified at the end of the 36-month study by
one local neurologist and JdP-C, at the Central Unit, using
the recent and prevailing Brighton Collaboration case-
definition categories [23, 24].
The AEMPS checked the presence of other possible
GBS cases reported as suspected adverse drug reactions
in the population covered by network hospitals. For
data-completion purposes, in 2012 we requested all hos-
pital pharmacies to provide information on registered
IVGG deliveries to wards for treatment of GBS patients
admitted during the period 2009–2012. These requests
did not add any new patient.
Clinical antecedents
We collected information on immunisations, including in-
fluenza vaccines, administered during the 42-day period
preceding clinical onset of suspected GBS. For other clin-
ical antecedents, we only investigated those occurring dur-
ing the 30-day period prior to clinical onset of suspected
GBS, namely, respiratory infections (fever with cough or
expectoration and other respiratory symptoms), gastro-
intestinal infections (nausea, vomiting, diarrhoea), other
infections, and other antecedents. We collected anteced-
ents through interviews with patients. The AEMPS, work-
ing in collaboration with the public health authorities,
would certify the vaccine received (brand, health centre
where the prescription was issued, and administration
date) in A(H1N1)pdm09 post-vaccination cases.
Database of hospital discharges
At the end of 2013, we requested the National Hospital In-
patient Registry to supply us with data on all patients aged
≥20 years admitted in the period 2009–2011 and having
International Classification of Diseases, Ninth Revision,
Clinical Modification (ICD-9-CM) code 357.0 (acute infect-
ive polyneuritis) as their principal or other diagnosis at dis-
charge. This registry constitutes a database on discharges
generated at all hospitals serving the Spanish National
Health Service, which provides services for the large major-
ity of the resident population country-wide and encom-
passes all hospitals in the surveillance network [25].
Ethical approval
This study was approved by the Research Ethics Com-
mittee at the Carlos III Institute of Health. All patients,
with no exceptions, gave their informed consent.
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Statistical analysis
We computed exact Poisson confidence intervals (CI)
for observed incidence rates for all, age groups, and gen-
ders [26]. We accepted as valid the background inci-
dence and threshold values obtained from the previous
study in 1998–1999, despite a possible change in hos-
pital admissions due to the widespread use of IVGG as
early treatment for GBS, including mild cases. We de-
fined alarm signals when post A(H1N1)pdm09 immun-
isation cases were notified by the network or the total
monthly incidence exceeded the estimated monthly
upper 95 % CI limit for background incidence [22].
Monthly upper 95 % CI limit for background incidence
had been calculated with ARIMA and Poisson models
[21]. Crude monthly incidences were calculated from
notifications and confirmed cases, and plotted on a
graph showing predicted values.
We checked the positive predictive value of ICD-9-
CM diagnostic code 357.0 in the Hospital In-patient
Registry against the judgment of a neurologist (JAG-M)
at one of the hospitals, the Puerta de Hierro University
Hospital in Majadahonda. For each centre, we estimated
a sensitivity value as the complementary of the false-
negative rate, defined as the ratio between the number
of notified and confirmed GBS cases not registered at
the National Hospital In-patient Registry over the total
number of notified and confirmed GBS cases. We calcu-
lated monthly incidences of hospital-admitted GBS
country-wide and plotted these on the epidemic curve
defined by the 95 % CI limits of expected incidences
depicted in the above-mentioned graph.
Results
GBS cases ascertained by the neurologist network
Figure 1 shows the geographical distribution of the 10
hospitals in the network. During the surveillance period,
January 2009-December 2011, local neurologists notified
148 patients with suspected GBS to the Central Unit. Of
these, 138 were confirmed as GBS and three as MFS,
making a total of 141 diagnoses confirmed by reference
to the NINDS criteria after a minimum follow-up of one
month. The positive predictive value of a suspected or
notified case was 141/148, 95 %, 95 % CI 90 % to 98 %.
When patients were re-classified according to Brighton
criteria, 81 (57 %), 54 (38 %), and 5 (4 %) met criteria for
levels 1, 2 and 3, respectively; one case (0.7 %) remained
unclassified due to lack of access to hospital records. Of
the seven patients excluded from the initially reported
total of 148, three had alternative neurological diagnoses
and four had a doubtful GBS diagnosis.
Of the 141 cases, 82 (58 %) were men; mean age at on-
set was 55.9 years (standard deviation 17.28 years); and
48 patients (34 %) were bed-bound one week after onset
(Table 1). Two patients with serious comorbidity died
within the first week of onset and a further four at a
later date.
Santiago de  
Compostela
Zaragoza
Madrid
Segovia
Granada
Toledo
Leganés
Majadahonda
L’Hospitalet 
de Llobregat
Malaga
Fig. 1 Geographical distribution of cities where study hospitals provided neurological care for Guillain-Barré syndrome. The inset shows Canary
Islands. This figure is slightly modified from Cuadrado et al. [22]. Copyright 2004, with permission of Springer
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GBS incidence according to the neurologist network
Table 2 shows the age- and sex-specific distribution of
cases and incidences. The annual incidence per 100,000
adult population was 1.20 for men and 0.81 for women.
Incidence increased with age, particularly among men,
up to the 70–79 age group. Table 3 shows the distribu-
tion of cases and incidence by hospital. Average annual
incidence per 100,000 ranged from 0.35 in Malaga to
2.51 in Santiago de Compostela.
GBS cases registered at the National Hospital In-patient
Registry
A total of 2383 patients were hospital-admitted country-
wide from 2009 to 2011 with ICD-9-CM code 357.0 as
their principal diagnosis. The number of registered pa-
tients with GBS admitted to the networked hospitals
across the period 2009–2011 was 193, 37 % higher than
the 141 notified and confirmed GBS and MFS cases,
with a several-fold variation in incidence among hospi-
tals. Thirty-five out of the 141 patients with confirmed
GBS reported by surveillance from 2009 to 2011 (25 %)
were not identified among those with GBS code 357.0 as
their principal diagnosis (sensitivity 75 %, 95 % CI 67 %
to 82 %). Likewise, the neurologist network reported 106
out of the 193 patients who were registered as admitted
from 2009 to 2011 to networked hospitals and dis-
charged with code 357.0.
The validation of ICD-9-CM code 357.0 for GBS diag-
nosis, recorded for 17 patients at the Puerta de Hierro
Hospital in Majadahonda, showed it to be wrong in
three cases, 18 %, which had in fact been diagnosed with
axonal polyneuropathy, chronic transformation of a pre-
vious GBS and non-inflammatory polyradiculoneuropa-
thy attributable to causes other than GBS. Hence, the
positive predictive value of such 357.0 coded diagnosis
was 82 %, 95 % CI 57 % to 96 %.
Table 1 Characteristics of confirmed GBS cases notified in 2009–2011 and identified by the neurologist network
Motor status at one week after clinical onset or hospital admission
Variables No. of patients (%) Independent gait Gait: able with support Able to stand up Bed-bound Unknown
Sex
Male 82 (58.2) 21 21 3 31 6
Female 59 (41.8) 18 22 0 17 2
Age group (years)
20–29 11 (7.8) 5 4 0 1 1
30–39 23 (16.3) 14 6 0 2 1
40–49 21 (14.9) 5 9 1 5 1
50–59 25 (17.7) 4 13 1 6 1
60–69 24 (17.0) 6 5 0 12 1
70–79 26 (18.4) 2 4 0 17 3
80+ 11 (7.8) 3 2 1 5 0
Clinical antecedent
Not identified 41 (29.1) 14 13 1 9 4
Recorded 100 (70.9) 25 30 2 39 4
Infection 85 (60.3) 21 27 2 32 3
—GTI 40 (28.4) 9 13 1 15 2
—ILI-RTI 34 (24.1) 11 9 1 12 1
—GI and ILI-RTI 3 (2.1) 0 1 0 2 0
—Urinary tract 3 (2.1) 0 2 0 1 0
—Other 4 (2.8) 1 2 0 1 0
—Unknown 1 (0.7) 0 0 0 1 0
Influenza vaccination 7 (5.0) 2 1 0 4 0
Othera 13 (9.2) 2 4 0 6 1
All patients 141a,b 39 (27.7) 43b (30.5) 3 (2.1) 48b (34.0) 8 (5.7)
GBS Guillain-Barré syndrome, GTI gastrointestinal tract infection, ILI-RTI influenza-like infection or respiratory tract infection
a“Other” encompasses surgery, medication, trauma, gastric carcinoma, delivery and pregnancy
bThe sum does not add up the total amount of patients because some patients had more than one antecedent
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Table 2 Observed incidence of GBS per 100,000 person-years for 2009–2011 in the population of 4.68 million under surveillance by the neurologist network
Male Female Total
Age group in years Cases Person-years Incidence 95 % CI Cases Person-years Incidence 95 % CI Cases Person-years Incidence 95 % CI
20–29 6 1,232,652 0.49 (0.18–1.06) 5 1,224,264 0.41 (0.13–0.95) 11 2,456,916 0.45 (0.22–0.80)
30–39 12 1,607,871 0.75 (0.39–1.30) 11 1,560,600 0.70 (0.35–1.26) 23 3,168,471 0.73 (0.46–1.09)
40–49 14 1,350,147 1.04 (0.57–1.74) 7 1,354,077 0.52 (0.21–1.07) 21 2,704,224 0.78 (0.48–1.19)
50–59 10 991,665 1.01 (0.48–1.85) 15 1,045,449 1.43 (0.80–2.37) 25 2,037,114 1.23 (0.79–1.81)
60–69 17 783,156 2.17 (1.26–3.48) 7 845,904 0.83 (0.33–1.71) 24 1,629,060 1.47 (0.94–2.19)
70–79 14 569,067 2.46 (1.34–4.13) 12 712,188 1.68 (0.87–2.94) 26 1,281,255 2.03 (1.33–2.97)
80+ 9 272,355 3.30 (1.51–6.27) 2 503,019 0.40 (0.05–1.44) 11 775,374 1.42 (0.71–2.54)
Total ≥20 years 82 6,806,913 1.20 (0.96–1.50) 59 7,245,501 0.81 (0.62–1.05) 141 14,052,414 1.00 (0.84–1.18)
GBS indicates Guillain-Barré syndrome, CI confidence interval
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Table 3 Hospitals and population coverage in numbers, GBS patients notified to the neurologist network, estimated sensitivity compared to patients coded as GBS in the
National Hospital In-patient Registry and incidence × 100,000
Hospital Person-years
≥20 years
Number of patients Proportions Incidence × 100,000
Number of
hospital-registered
patientsa
Notified
patients
Notified and
confirmed GBS
(a)
Confirmed
not hospital
registered (b)
Infection in
preceding
30 days
Influenza vaccine
in preceding
42 days
Confirmed not
registered over notified
and confirmed (b/a)
Estimated
sensitivity
1-(b/a)
in
registered
patientsa
in
notified
patients
Carlos Haya Hospital
(Malaga)
3,676,698 19 13 13 4 8 0 0.31 0.69 0.52 0.35
General Hospital
(Segovia)
364,983 6 4 4 0 3 0 0.00 1.00 1.64 1.10
La Paz University
Hospital (Madrid)
1,239,486 27 19 18 5 10 2 0.28 0.72 2.18 1.45
Miguel Servet University
Hospital (Zaragoza)
1,023,261 13 11 9 1 3 0 0.11 0.89 1.27 0.88
Bellvitge University
Hospital (Hospitalet
de Llobregat)
3,034,845 31 20 20 7 11 2 0.35 0.65 1.02 0.66
Puerta de Hierro
University Hospital
(Majadahonda)
967,029 17 15 14 0 8 0 0.00 1.00 1.76 1.45
Severo Ochoa University
Hospital (Leganés)
472,563 8 5 5 0 3 0 0.00 1.00 1.69 1.06
Virgen de la Salud
Hospital (Toledo)
1,003,170 16 17 16 6 11 0 0.38 0.63 1.59 1.59
Virgen de las Nieves
University Hospital
(Granada)
1,115,721 18 15 13 4 8 0 0.31 0.69 1.61 1.17
University Hospital
Clínico (Santiago
de Compostela)
1,154,658 38 29 29 8 20 3 0.28 0.72 3.29 2.51
Total 14,052,414 193 148 141 35 85 7 0.25 0.75 1.37 1.00
GBS Guillain-Barré syndrome
aPatients admitted to the respective hospitals during the period 2009–2011 and discharged with ICD-9-CM code 357.0 as their principal diagnosis
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Vaccination and other antecedents
One hundred cases (71 %) had a record of potential ex-
posures (Table 1), with 85 (60 %) patients having had in-
fections, 7 (5 %) having received immunisations with
influenza vaccine within the 42 days prior to clinical on-
set and 13 (9 %) having other antecedents.
Table 4 shows demographic and clinical data for the
seven cases with vaccination, who were admitted to
three different hospitals. All cases fulfilled Brighton
level-1 criteria. Four had received a 2009-TIV prior to
A(H1N1)pdm09 campaign, and one of these was simul-
taneously affected by a bronchopulmonary infection as a
clinical antecedent. None had received A(H1N1)pdm09
vaccine. Another three cases had received a 2010–2011-
TIV immunisation containing the A(H1N1)pdm09
strain, one in the 2010 campaign and two in 2011. Four
out of seven GBS cases preceded by influenza vaccin-
ation were bed-bound compared with 43 of 134 other
GBS cases (Tables 1 and 4).
As no GBS case related to A(H1N1)pdm09 vaccination
was found we did not send any alarm signal to health
authority, the AEMPS.
Figure 2 depicts the monthly/seasonal incidence of
GBS in patients grouped by age and type of most
Table 4 Neurologist network: demographic and clinical data pertaining to seven GBS patients with influenza immunisations during
the 42-day period preceding clinical onset
Patient ref.
no., sex,
age
Vaccination date
and type (a)
Co-morbidity or clinical
antecedent in 30 days
prior to onset
Symptom
onset (b)
(a-b) Interval
in weeks
Functional
level at
one week
Treatment Clinical confirmation
on the basis of
1
Female
53
2 Oct 2009 Motor neurone disease 13 Oct 2009 1–2 Walking Not treated Clinical symptoms/
exam.
2009-TIV Cerebrospinal fluid
(CSF) tests
Electrophysiology lab.
Other causes excluded
2
Male
68
27 Oct 2009 Heart disease. 22 Nov 2009 3–4 Bed-bound IVGG Electrophysiology lab.
2009-TIV Sleep apnea. High blood
pressure. Bronchopulmonary
infection
Other causes excluded
3
Male
34
20 Oct 2009 Syphilis seropositive 30 Nov 2009 5–6 Walking IVGG Clinical symptoms/
exam.
2009-TIV CSF tests
Electrophysiology lab.
Other causes excluded
4
Male
70
28 Sept 2009 Motor neurone disease 10 Oct 2009 1–2 Bed-bound IVGG Clinical symptoms/
exam
2009-TIV CSF tests
Electrophysiology lab.
Other causes excluded
5
Male
77
18 Oct 2010 - 1 Nov 2010 2 Bed-bound IVGG Clinical symptoms/
exam.
2010–2011-TIVa Electrophysiology lab.
Other causes excluded
6
Female
78
5 Jan 2011 - 15 Jan 2011 1–2 Able to walk
with support
IVGG Clinical symptoms/
exam.
2010–2011-TIV CSF tests
Electrophysiology lab.
Other causes excluded
7
Male
82
27 Oct 2011 High blood pressure 23 Nov 2011 4 Bed-bound IVGG
Mechanical
Ventilation
Clinical symptoms/
exam.
2010–2011-TIVa DM CSF tests
Atrial fibrillation Electrophysiology lab.
Other causes excluded
GBS Guillain-Barré syndrome, DM diabetes mellitus type 2, TIV seasonal trivalent influenza vaccine, IVGG intravenous gammaglobulin
aReceived the vaccine Chiromas® (Novartis), adjuvanted with MF59C.1
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frequent antecedent. The seasonal distribution suggested
the highest incidence in January and February, particu-
larly for patients aged ≥60 years and for those with pre-
vious ILI-RTI or GTI.
2009-2011 GBS incidence compared with background
incidence
Figure 3 gives an overview of the incidence and anteced-
ents during the surveillance period compared to the pre-
dicted background incidence. Monthly incidences of
notified and confirmed GBS did not exceed the 95 %
upper confidence limit but did exceed the lower limit
several times in 2010 and 2011. GBS rates from National
Hospital In-patient Registry were generally higher than
those calculated from notified patients, particularly after
the 2010-2011-TIV campaign, and occasionally exceeded
the upper limit of the epidemic prediction, though not
for the period October-November 2009 when the four
post-2009-TIV cases were observed or the period follow-
ing the A(H1N1)pdm09 vaccination campaign.
Discussion
The performance of our surveillance of GBS as a potential
adverse reaction of influenza immunisations rests on the
coincidence of time-related clustering of GBS cases occur-
ring within the 42-day, high-risk post-immunisation
period with a greater-than-expected increase in GBS inci-
dence. Overall, monthly incidence of GBS, whether noti-
fied or registered country-wide, does not appear to reflect
any impact of A(H1N1)pdm09 or seasonal vaccine cam-
paigns. Our neurologist network failed to find a single
GBS case following A(H1N1)pdm09 vaccination. The
Hospital In-patient Registry suggested no increase in GBS
monthly incidence during or post influenza immunisation
campaigns.
Our study might have some limitations. The power of
this study to detect an increase in incidence in vaccinated
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Fig. 2 Seasonal patterns of Guillain-Barré syndrome (GBS) according to the neurologist network. Top: monthly incidence of GBS in two age
groups. Bottom: case distribution by type of preceding infection and month of clinical onset
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persons depends on the method of determination of the
threshold, on the relative risk of GBS in vaccinated per-
sons, and on the proportion of the population that re-
ceived the vaccine. Since only a small part of the
population was vaccinated with A(H1N1)pdm09, the rela-
tive risk associated with vaccination should have been very
high to induce an overall incidence of GBS sufficiently
high to exceed the threshold. However, we did not find
any GBS case following A(H1N1)pdm09 vaccination in
the 165,000 population vaccinated, despite an expected
background incidence around 2.62 cases from December
to March, which makes increased incidence associated
with vaccination highly unlikely. Another limitation is the
difficulty in adjusting for confounding from causes such
as ILI-RTI or GTI, both of which are unlikely in our series
in the light of the lack of such antecedents in six of our
seven cases. Furthermore, potential underreporting might
have happened, as has been suggested in connection with
paediatric and medical departments in Sweden, where a
similar GBS surveillance system was in place [27]. In our
study, only one reported GBS case was not hospital-
admitted but similar cases may have been overlooked.
Underreporting in autumn 2009, linked to considerable
media attention paid to influenza-related events during
the influenza monovalent vaccine campaign, was probably
lower than during other surveillance periods. Additionally,
National Hospital In-patient Register has a proportion of
false positive and false negative cases whose impact on
this registry’s ultimate validity for estimating all GBS cases
is uncertain [28]. Likewise, we assumed that background
incidence estimated in 1999 would remain the same
10 years later, despite the potential change in infection
transmissibility caused by the increase in population dens-
ity in Spain over this period. Neither can exposure mis-
classification be ruled out since recall bias might have
affected vaccination ascertainment. Our study also lacks
power to study the individual effects of every vaccine adju-
vant. Lastly, one of the post-2009-TIV Spanish cases had
preceding ILI-RTI episodes, and two others had motor
function potentially compromised by motor neurone dis-
ease. One could thus speculate that co-morbidity may
have contributed to vaccination being indicated. High im-
munisation frequencies and improved information might
have mimicked excess post-2009-TIV GBS among the
surveillance population in both Spain and the United
Kingdom [29].
Our results are consistent with a study by Burwen et
al. [16] on GBS incidence after influenza vaccination
among the Medicare population in 2009–2010, which
failed to find an increase in GBS incidence above a crit-
ical limit established by GBS incidence in the previous
five years. In contrast, our results differ from the modest
risk excess reported in three pooled analyses [9–11].
However, the main design of these reviews, namely, self-
controlled case series analysis and self-controlled
interval-risk design, might imply a high risk of bias, i.e.,
recall bias for exposures predating GBS onset by more
than 42 days and, in particular, incomplete adjustment
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for potential confounders like ILI-RTI or GTI and sea-
sonal patterns of GBS onset [30, 31]. On the other hand,
cohort studies either give lower relative risks [11, 15, 32]
or fail to find any association [12–14].
Contrary to the findings of the ITANG study, which
used a 176-patient case–control and case-series designs
and reported modest but positive associations with
2010-TIV [33], we failed to observe any suspected im-
pact of either the 2010 or the 2011 seasonal immunisa-
tion. Doubts nevertheless continue to surround ITANG’s
capacity to remove residual confounding from the
several-fold higher effect of the preceding infections,
odds ratio (OR) = 23.8 and OR = 11.5 for ILI-RTI or
GTI, respectively. Even so, the most important reason
for suspecting a high risk of bias in the ITANG study is
control selection towards low 2010-2011-TIV immunisa-
tion rates in hospital controls. ITANG controls were re-
cruited from among patients with trauma, after
eliminating those with chronic conditions, a selection
strategy that would potentially exclude people in whom
2010-2011-TIV had been indicated.
One important aspect of our results regarding the four
cases associated with the 2009-TIV and not with preced-
ing infections is that they might match the intriguing asso-
ciation observed in the UK for the same exposure and
time as reported by the VAESCO study. The VAESCO
study reported an excess GBS risk for the unadjuvanted
2009-TIV in the UK [34], not seen in previous years using
the same UK database [29]. The fact that such an effect
was not observed in other seasonal influenza vaccines in
2010 or 2011 in Spain might point to a side-effect of the
2009-TIV due either to the A/Brisbane/59/2007(H1N1) or
to the A/Brisbane/10/2007(H3N2) component of the 2009
TIV being removed from the 2010-2011-TIV.
Our study design, when compared to the other three
procedures used to monitor or disclose potential causes of
GBS, i.e., the spontaneous reporting of suspected adverse
drug reactions, self-controlled case series and case–con-
trol analysis, raises public health service-related questions
about preferential or alternative procedures when facing
early detection of a potential excess risk of GBS. It would
appear that methodological issues and logistic elements
related to the question to be answered are paramount.
Speed in activating surveillance resources may constitute
a key issue. Self-controlled case-series analysis in New
York based on a list of 150 active-reporting neurologists
and 2495 passive-reporting neurologists based in neur-
ology departments, was considered expensive [35]. Our
system, relying on hospital neurology departments, took
advantage of the National Health Care Services which, on
a geographical residential basis, covered well-defined pop-
ulations, was underpinned by a small number of neurolo-
gists and was conducted at no extra cost. Spain’s National
Health Care system is operated by regional authorities and
the AEMPS is a state-owned institution. The Spanish
neurologist network was intensively active during the
A(H1N1)pdm09 campaign, i.e., though the low monthly
rates in 2010 and 2011 might have been related to under-
reporting. Reduction of surveillance to the November
2009-March 2010 period or express official support from
the regional authorities for the purpose of incorporating
public health missions in neurology departments might
have improved GBS surveillance.
It would appear that GBS case–control studies using
population controls and embodied in a hospital- and
population-based network may be the best alternative for
populations covered by publicly operated medical systems.
This option does not exclude the addition of other proce-
dures, such as self-controlled GBS case series, whether or
not nested within an immunised cohort. At all events,
knowledge of the GBS epidemiology in the study popula-
tion is advantageous, particularly because asymmetry of
exposure and confounder measurement in non-high-risk
periods or among controls appears to be inevitable. Al-
though A(H1N1)pdm09 monovalent vaccine is no longer
in use, its strain has been incorporated in the seasonal
vaccines of the following years, so that our study results
are still of practical significance. All things considered, an
effective influenza vaccine might reduce GBS incidence
through reductions in ILI-RTI infections, a far more fre-
quent antecedent to GBS than is vaccination, as shown by
our results.
Conclusions
We conclude that increased GBS incidence due to
A(H1N1)pdm09 or TIV immunisations during 2010–2011
over background GBS is unlikely. Efficient GBS surveil-
lance requires the local support of public health author-
ities and methodological updates, in line with the
designated purpose in each case.
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